Grounded in patient interviews
The development work identified gaps around mental health, family impact, travel and financial burden, and effects on work and home life.
Instrument PROM-UM
Patient-Reported Outcome Measure for Uveal Melanoma
A validated uveal melanoma questionnaire for post-brachytherapy symptoms, worry, and discomfort.
PROM-UM is a patient-reported outcome measure for adults treated with plaque brachytherapy for uveal melanoma. It was built from patient interviews about ocular oncology quality of life and validated in 439 patients from three North American ocular oncology centres.
About
Learn about PROM-UM
PROM-UM was developed because existing ophthalmic oncology quality-of-life tools did not fully capture what uveal melanoma patients described as important after treatment.
Validated for post-brachytherapy care
The psychometric study used classical test theory and item response theory to evaluate PROM-UM in patients treated with brachytherapy for uveal melanoma.
Built for implementation
PROM-UM is intended for research, registries, clinical monitoring, quality improvement, and structured follow-up after ocular brachytherapy.
Validation
What PROM-UM measures
The 2023 validation study identified three PROM-UM domains and reported acceptable performance across most aspects of the instrument.
Domain 1
Symptom Impairment
Captures problems such as vision-related impairment, mental health concerns, and difficulty with regular activities.
Domain 2
Worry
Captures concerns about recurrence, metastasis, and the ongoing uncertainty that can follow uveal melanoma treatment.
Domain 3
Discomfort
Captures post-treatment ocular discomfort, including pain, pressure, and irritation around the eye or socket.
Evidence
Development and validation papers
PROM-UM is supported by peer-reviewed development and psychometric validation work in uveal melanoma and ocular oncology patient-reported outcomes.
Development paper
The use of semistructured interviews to assess quality of life impacts for patients with uveal melanoma
Kopp, Crump, and Weis conducted a qualitative study of 10 patients treated with brachytherapy through the Alberta Ocular Brachytherapy Program. The study identified quality-of-life constructs missing from the EORTC QLQ-OPT30 and supported the need for a uveal melanoma-specific patient-reported outcome measure for point-of-care use.
View articleValidation paper
Psychometric Results of a New Patient-Reported Outcome Measure for Uveal Melanoma Post-Brachytherapy Treatment: The PROM-UM
Weis, Jiang, Skalet, Shields, and Crump evaluated PROM-UM in 439 patients from the University of Alberta, Wills Eye Hospital, and Casey Eye Institute. The study identified Symptom Impairment, Worry, and Discomfort domains and reported acceptable reliability and item performance, while noting areas for future research.
View articleCite
How to cite PROM-UM
Please cite both the qualitative development paper and the psychometric validation paper when using PROM-UM in research, clinical studies, registries, or implementation work.
Kopp BC, Crump RT, Weis E. The use of semistructured interviews to assess quality of life impacts for patients with uveal melanoma. Canadian Journal of Ophthalmology. 2017. doi:10.1016/j.jcjo.2016.10.005
Weis E, Jiang J, Skalet AH, Shields CL, Crump RT. Psychometric Results of a New Patient-Reported Outcome Measure for Uveal Melanoma Post-Brachytherapy Treatment: The PROM-UM. Cancers. 2023;15:4142. doi:10.3390/cancers15164142
Licensing
Choose the license that matches your use
A PROM-UM license is required before using, reproducing, distributing, translating, adapting, or electronically implementing the instrument.
Academic / non-profit
No fee
For investigator-led academic research, student projects, and non-profit quality improvement where PROM-UM is not part of a commercial product or sponsored trial.
Clinical use
$500/year USD
For routine care, institutional registries, clinical monitoring, and quality programs. Covers one clinical group of up to 20 PROM-UM users.
Commercial / trial use
$35-$70 USD per use
For industry-sponsored trials, contract research, digital health products, electronic platforms, or other commercial implementations.
Estimate
Approximate your fee
Use this guide for planning. All prices are listed in USD. Final fees and permitted uses are confirmed during registration.
| Use type | Typical examples | Indicative fee |
|---|---|---|
| Academic / non-profit | Unfunded or grant-funded academic studies, theses, non-profit QI | No fee |
| Clinical | Clinic groups, hospital programs, registry-based care monitoring | $500/year USD per group of 20 users |
| Commercial / clinical trial | Sponsored studies, CRO use, licensed electronic capture, product integration | $35-$70 USD per completed use |
FAQ
Common questions
Short answers for researchers, clinicians, trial teams, and digital health groups evaluating whether PROM-UM is the right uveal melanoma patient-reported outcome measure for their work.
What is PROM-UM?
PROM-UM is a validated patient-reported outcome measure for adults treated with brachytherapy for uveal melanoma. It measures symptoms and their impact, worry, and ocular discomfort after treatment.
What makes PROM-UM different from broader quality-of-life tools?
PROM-UM is specific to uveal melanoma after ocular brachytherapy. Its development was informed by patient interviews that identified issues such as mental health, family impact, travel and financial burden, and work and home life.
Who can use PROM-UM?
Academic researchers, non-profit teams, clinical programs, registries, industry-sponsored studies, and digital health platforms may request permission to use PROM-UM under the appropriate license.
Is PROM-UM available for electronic implementation?
Electronic implementation can be reviewed during registration. Requests should describe the platform, intended workflow, number of users or participants, and whether the instrument will be translated or adapted.
Register
Register to use PROM-UM
Send a short registration request and we will confirm the appropriate license, fee category, and next steps.
Include these details
- Your name, institution, and contact email
- Intended use: academic, clinical, commercial, or trial
- Study, clinic, registry, or platform name
- Expected number of participants, sites, or users
- Whether electronic implementation or translation is planned